Association of Dual SGLT-2 Inhibitor and GLP-1 Receptor Agonist Therapy with Colon Cancer Risk in Post-Polypectomy Patients with Diabetes: A Target Trial Emulation
Wang CH, Chang WC, Chen HY, Chen PH, Lin MH, Lee CH
Summary
This target trial emulation study examined whether dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy reduces colon cancer recurrence risk in diabetic patients after polypectomy. Using the TriNetX global federated database, researchers compared cancer outcomes in patients receiving combination therapy versus monotherapy or neither agent. The study adds to growing evidence that GLP-1 RAs may have chemopreventive properties beyond glycemic control.
Clinical Significance
Emerging data suggesting GLP-1 receptor agonists may reduce colorectal cancer risk could fundamentally change how we think about these medications — not just as glucose-lowering and weight-loss agents, but as potential cancer chemoprevention tools. This is particularly relevant for diabetic patients at elevated CRC risk who are already candidates for GLP-1 RA therapy.
Key Findings:
- Target trial emulation using the TriNetX global health records network
- Examined dual SGLT-2i + GLP-1 RA combination vs. monotherapy in post-polypectomy T2D patients
- Builds on prior evidence including Wang et al. (JAMA Oncol, 2024) and Bushi et al. (Health Sci Rep, 2025) showing GLP-1 RA association with reduced CRC risk
- Mechanistic plausibility via anti-inflammatory pathways (Bendotti et al., 2022) and mTOR modulation
Clinical Takeaway: For prescribers managing T2D patients with history of colorectal polyps, GLP-1 RA therapy may offer an additional protective benefit against CRC recurrence — an important consideration in medication selection.
Links:
Relatert forskning
Determinants of VO2peak Responsiveness to Aerobic Exercise Training in Adults with Type 2 Diabetes: The PROTECTION Study
In 108 adults with Type 2 diabetes participating in a 26-week supervised cycling programme, GLP-1 re…
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis evaluated the association between GLP-1 receptor agonist use and de…
GLP-1 Receptor Agonist Therapy in Adults With Sickle Cell Disease and Type 2 Diabetes: A Real-World Cohort Analysis
This real-world study of 1,391 matched patients with sickle cell disease (SCD) and type 2 diabetes f…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…